Quanterix Corporation (QTRX) Guidance & Earnings Results

On 2026-08-10 Quanterix Corporation lowered guidance: "Revenue guidance cut from $169-174M to $142-148M; non-GAAP gross margin guidance cut from 49-53% to 48-50%; year-end cash guidance cut from ~$100M to…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

QTRXQuanterix CorporationFollow QTRX — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 135.3M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 10 Nov, in 17 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
10 Aug 26	Lowered	Revenue guidance cut from $169-174M to $142-148M; non-GAAP gross margin guidance cut from 49-53% to 48-50%; year-end cash guidance cut from ~$100M to ~$80M. · full year
6 May 26	Reaffirmed	Revenue $169-174M; GAAP gross margin 41-45%; adjusted gross margin 49-53%; year-end cash ~$100M · full year
2 Mar 26	Raised	FY2026 revenue guidance $169-174M vs FY2025 revenue $138.9M, implying ~23% growth at midpoint
8 Jan 26	Raised	Exceed revenue and cash guidance for FY2025 · full year
10 Nov 25	Reaffirmed	FY2025 revenue $130-135M; gross margin 45-47%; cash usage $34-38M · full year
7 Aug 25	Lowered	FY2025 revenue $130-135M (from prior implied ~$140M+); GAAP gross margin 49-53%; adjusted gross margin 45-49%; adjusted cash usage $34-38M; exit cash ~$120M · full year

Quanterix Corporation — questions

What guidance did Quanterix Corporation give?: On 2026-08-10: "Revenue guidance cut from $169-174M to $142-148M; non-GAAP gross margin guidance cut from 49-53% to 48-50%; year-end cash guidance cut from ~$100M to ~$80M."
When does Quanterix Corporation report earnings?: Quanterix Corporation's next earnings report is expected on 2026-11-10.

Every figure on this page comes from Quanterix Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.